Fortrans Eziclen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Fortrans eziclen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Fortrans Eziclen Today - Breaking & Trending Today

Critical Comparison: Ipsen (OTCMKTS:IPSEY) & Alpha Teknova (NASDAQ:TKNO)

Ipsen (OTCMKTS:IPSEY – Get Rating) and Alpha Teknova (NASDAQ:TKNO – Get Rating) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability. Valuation & Earnings This table compares Ipsen and Alpha Teknova’s top-line […] ....

United States , Fortrans Eziclen , Suppositoria Glycerini , Alpha Teknova , Alpha Teknova Company Profile Get Rating , Therapeutics Inc , Alpha Teknova Inc , Ipsen Company Profile Get Rating , Rhythm Pharmaceuticals , Get Rating , Given Ipsen , Company Profile , Smectaflora Protect , Blueprint Medicines , Tersera Therapeutics , Braintree Laboratories , Teknova Company Profile , Otcmkts Ipsey , Stock Comparison , Stock Analysis ,

Ipsen Presents Strong Full-Year 2021 Results and Enters Into Exclusive Negotiations to Divest Its Consumer Healthcare Business

Strong 2021 financial performance with total-sales growth of 12.3% at CER1 (growth of 10.7% as reported) and a core operating margin of 35.2% (IFRS operating margin of 29.6%) Exclusive negotiations ....

France General , United States , Republic Of , United Kingdom , South Korea , Mayoly Spindler , Gwenan White , Fortrans Eziclen , Ioana Piscociu , David Loew , Ipsen Euronext , Blueprint Medicines Corporation , Company Social Responsibility , Other Business Development , Leadership Team , Therapeutics Inc , Foreign Exchange , International Court , Public Affairs , Global Leadership Team , European Medicines Agency , Health Canada , Business Development , Consumer Healthcare , Chief Executive Officer , Specialty Care ,

Ipsen Delivers Strong Sales Growth for the First Nine Months and Improves Its Full-Year Guidance

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, publishes its sales performance for the third quarter of 2021 and the year to date. Sales ....

France General , United States , Republic Of , United Kingdom , South Korea , Fanny Allaire , Gwenan White , David Loew , Fortrans Eziclen , Ipsen Euronext , Global Communications , Public Affairs , European Medicines Agency , Drug Administration , Regulatory News , Specialty Care , Chief Executive Officer , Accent Therapeutics , Nucleic Acids , Spherical Nucleic Acids , New Drug Application , Priority Review , European Medicines , Rare Disease , Consumer Healthcare , Sponsored Leveli American Depositary Receipt ,

Ipsen : Delivers Encouraging Sales Growth in the First Quarter of 2021 Despite the Pandemic, and Confirms Its Full-Year Guidance

Ipsen : Delivers Encouraging Sales Growth in the First Quarter of 2021 Despite the Pandemic, and Confirms Its Full-Year Guidance
04/22/2021 | 01:01am EDT
Send by mail :
Message :
Regulatory News:
Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, publishes its sales performance for the first quarter of 2021:
Q1 2021 sales summary
Highlights
Total Sales growth of 5.5% at CER, or 0.6% as reported, to €658.5m, despite impact of the pandemic
An increase in Specialty Care sales of 6.4%
1 to €611.5m, driven by the growth of Cabometyx
® (
A Consumer Healthcare sales decline of 5.4%
1 to €47.0m, reflecting the ongoing effects of COVID-19, partly offset by recovery in China ....

United States , France General , United Kingdom , David Loew , Fortrans Eziclen , Ipsen Euronext , Fusion Pharmaceuticals Inc , European Commission , Regulatory News , Specialty Care , Consumer Healthcare , Chief Executive Officer , Total Sales , Reference Member State , Decentralized Procedure , Fusion Pharmaceuticals , Annual Shareholder Meeting , Rare Disease , Sponsored Leveli American Depositary Receipt , North America , Middle East , Western European , Eastern Europe , Latin America , French Autorit , Des March ,

Ipsen Delivers Encouraging Sales Growth in the First Quarter of 2021 Despite the Pandemic, and Confirms Its Full-Year Guidance

Press release content from Business Wire. The AP news staff was not involved in its creation.
Ipsen Delivers Encouraging Sales Growth in the First Quarter of 2021 Despite the Pandemic, and Confirms Its Full-Year Guidance
April 22, 2021 GMT
Regulatory News:
Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, publishes its sales performance for the first quarter of 2021:
Q1 2021 sales summary
Highlights
Total Sales growth of 5.5% at CER, or 0.6% as reported, to €658.5m, despite impact of the pandemic
An increase in Specialty Care sales of 6.4% 1 to €611.5m, driven by the growth of Cabometyx ® (
cabozantinib ), Decapeptyl ® (
botulinum toxin type A )
A Consumer Healthcare sales decline of 5.4% 1 to €47.0m, reflecting the ongoing effects of COVID-19, partly offset by recovery in China ....

France General , United States , United Kingdom , Fanny Allaire , Gwenan White , David Loew , Fortrans Eziclen , Ipsen Euronext , Fusion Pharmaceuticals Inc , Global Communications , Public Affairs , European Commission , Specialty Care , Consumer Healthcare , Chief Executive Officer , Total Sales , Reference Member State , Decentralized Procedure , Fusion Pharmaceuticals , Annual Shareholder Meeting , Rare Disease , Sponsored Leveli American Depositary Receipt , North America , Middle East , Western European , Eastern Europe ,